Search
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
Benvitimod Recombinant Mouse Monoclonal Antibody (4A11)
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
图: 1 / 1
Benvitimod Antibody (MA566623) in SDS-PAGE
SDS-PAGE characterization of Benvitimod under reducing conditions. Lane M: Protein marker (kDa); Lane BVM: Purified Benvitimod Recombinant Monoclonal (Product # MA566623). Benvitimod showing heavy chain (~50 kDa) and light chain (~25 kDa). Gels were stained with Coomassie Brilliant Blue R-657.
产品信息
MA566623
产品规格
种属反应
Chemical
宿主/亚型
Mouse
/ IgG
Expression System
CHO cells
分类
Recombinant Monoclonal
类型
Antibody
克隆号
4A11
抗原
Conjugate of BVM hapten and KLH.
偶联物
形式
Liquid
浓度
7.1 mg/mL
纯化类型
Protein G
保存液
PBS
内含物
0.09% sodium azide
保存条件
-20°C
运输条件
Ambient (domestic); Wet ice (international)
靶标信息
Benvitimod is an aryl hydrocarbon receptor (AhR) immunomodulator primarily used in the treatment of psoriasis and atopic dermatitis. It functions by inhibiting the phosphorylation of STAT6, thereby preventing the downregulation of tight junction proteins induced by interleukins IL-4 and IL-13. This mechanism helps maintain skin barrier integrity and reduces inflammation. Benvitimod also impedes keratinocyte proliferation by inhibiting CDK4/6 and suppressing the JAK/STAT3 pathway, which is crucial for cell cycle progression. The drug has shown efficacy and tolerability in clinical trials, particularly for patients with mild to severe psoriasis, and has recently completed phase 3 trials. Benvitimod is applied topically, making it a convenient option for managing skin conditions with a body surface area involvement of 1-20%.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
